Biotech company Prothena said on Monday that its drug to treat AL Amyloidosis, a rare disease in which amyloid protein builds up in the body and disrupts organ function, failed a key trial. The drug, NEOD001, failed a phase 2 trial, and the company decided to discontinue its later-stage phase 3…
News
- A biotech company's farthest-along drug just failed a key trial — and the stock is plummeting (PRTA)
- Life Sci Veteran Garabedian Talks Up Biotech Accelerator in Texas
Xconomy Texas —. San Antonio — For early stage researchers at universities and other institutions, the idea of finding enough money to bring a drug or medical device to market can seem daunting, if not entirely hopeless. Grants and angel networks can cover some preclinical funding, and big…
- China auto show highlights industry's electric ambitions
BEIJING (AP) — The biggest global auto show of the year showcases China's ambitions to become a leader in electric cars and the industry's multibillion-dollar scramble to roll out models that appeal to price-conscious but demanding Chinese drivers. Auto China 2018, which opens this week, follows…
- Rackspace hires new C-Suite execs
The San Antonio-based business, which sells information technology services in the cloud, tapped Gerard Brossard as executive vice president of OpenStack ... D'Annunzio replaces Aimee Hoyt, who worked in that role from August 2015 to December 2017 and now leads human resources for biotech…
- Murray leads after windy day in Texas
SAN ANTONIO – Grayson Murray fixed a flaw in his swing and hit the ball well enough that blustery conditions weren't an issue for him Thursday in the Valero ... Theodore is a professor of neurosurgery, orthopedics and biomedical engineering at Johns Hopkins University School of Medicine as well…